Spectrum of Central Anticholinergic Adverse Effects Associated with Oxybutynin: Comparison of Pediatric and Adult Cases - 09/08/11
Doi : 10.1016/j.jpeds.2009.01.074
Paula Gish, RPh a, ⁎ 
, Andrew D. Mosholder, MD, MPH a, Melissa Truffa, RPh a, Rosemary Johann-Liang, MD b
, Andrew D. Mosholder, MD, MPH a, Melissa Truffa, RPh a, Rosemary Johann-Liang, MD b a Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, The United States Food and Drug Administration, Silver Spring, MD
b Health Resources and Services Administration, Department of Health and Human Services, Rockville, MD
Reprint requests: Paula Gish, RPh, Food and Drug Administration, White Oak Building 22, Room 3404, 10903 New Hampshire Ave, Silver Spring, MD 20993.Abstract |
We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases.
Le texte complet de cet article est disponible en PDF.Mots-clés : CNS, FDA
Plan
| No official support or endorsement by the U.S. Food and Drug Administration is intended or should be inferred. The authors declare no conflicts of interest. |
© 2009
Mosby, Inc. Tous droits réservés.
Vol 155 - N° 3
P. 432-434 - septembre 2009 Retour au numéro
Article précédent
- Omental Infarction in Children
- Ayelet Rimon, Alan Daneman, J. Ted Gerstle, Savithiri Ratnapalan
- Two Brothers with Ataxia-Telangiectasia-like Disorder with Lung Adenocarcinoma
- Naoki Uchisaka, Naomi Takahashi, Masaki Sato, Akira Kikuchi, Shinji Mochizuki, Kohsuke Imai, Shigeaki Nonoyama, Osamu Ohara, Fumiaki Watanabe, Shuki Mizutani, Ryoji Hanada, Tomohiro Morio
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?